NCT05825625View on ClinicalTrials.gov

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 26, 2023

Primary Completion Date

December 1, 2026

Study Completion Date

June 1, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Atezolizumab

Atezolizumab 1,200 mg by IV infusion Q3W.

DRUG

Tiragolumab

Tiragolumab by IV infusion Q3W.

Trial Locations (2)

45147

Universitätsklinikum Essen (AöR)-Westdeutsches Tumorzentrum Essen, Essen

69126

Thoraxklinik Heidelberg, Heidelberg

All Listed Sponsors
collaborator

Thoraxklinik-Heidelberg gGmbH

OTHER

collaborator

Roche Pharma AG

INDUSTRY

lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER